Comparison of CryoLife Inc. (CRY) and Nemaura Medical Inc. (NASDAQ:NMRD)

This is a contrast between CryoLife Inc. (NYSE:CRY) and Nemaura Medical Inc. (NASDAQ:NMRD) based on their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation. The two companies are Medical Appliances & Equipment and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CryoLife Inc. 26 48.62 35.96M 0.04 713.14
Nemaura Medical Inc. 4 0.00 6.66M -0.24 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 shows us CryoLife Inc. and Nemaura Medical Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
CryoLife Inc. 135,954,631.38% 0.6% 0.3%
Nemaura Medical Inc. 160,146,199.53% 0% 0%

Volatility and Risk

A beta of 0.66 shows that CryoLife Inc. is 34.00% less volatile than S&P 500. Competitively, Nemaura Medical Inc.’s 110.00% volatility makes it less volatile than S&P 500, because of the -0.1 beta.


CryoLife Inc.’s Current Ratio is 4.3 while its Quick Ratio is 3.2. On the competitive side is, Nemaura Medical Inc. which has a 1.8 Current Ratio and a 1.6 Quick Ratio. CryoLife Inc. is better positioned to pay off short and long-term obligations compared to Nemaura Medical Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for CryoLife Inc. and Nemaura Medical Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CryoLife Inc. 0 0 2 3.00
Nemaura Medical Inc. 0 0 0 0.00

$33 is CryoLife Inc.’s average target price while its potential upside is 11.90%.

Institutional and Insider Ownership

Roughly 77.8% of CryoLife Inc. shares are owned by institutional investors while 0.01% of Nemaura Medical Inc. are owned by institutional investors. Insiders owned 0.9% of CryoLife Inc. shares. Comparatively, 70.32% are Nemaura Medical Inc.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CryoLife Inc. 0.93% 8.24% -6.73% -15.39% -17.3% -12.05%
Nemaura Medical Inc. -9.91% -29.65% -38.86% -40.62% -72.09% -42.94%

For the past year CryoLife Inc. has stronger performance than Nemaura Medical Inc.


CryoLife Inc. beats Nemaura Medical Inc. on 10 of the 12 factors.

CryoLife, Inc., together with its subsidiaries, manufactures and distributes medical devices worldwide. It also processes and distributes implantable human tissues for use in cardiac and vascular surgeries. The company operates in two segments, Medical Devices and Preservation Services. It offers surgical sealants and hemostats, including BioGlue Surgical Adhesive, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; BioFoam Surgical Matrix, which is used as an adjunct in sealing abdominal parenchymal tissues, as well as an adjunct for hemostasis in cardiovascular surgery; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser console system and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina; and On-X heart valves for aortic and mitral indications. In addition, it distributes ProCol vascular bioprosthesis, a biological graft that provides vascular access for end-stage renal disease in hemodialysis patients; and PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities. Further, it distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using its proprietary SynerGraft technology; and vascular preservation services, such as CryoVein and CryoArtery tissues to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Nemaura Medical Inc., through its subsidiaries, discovers, develops, and commercializes specialty medical devices. It provides sugarBEAT device, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. The company was founded in 2009 and is headquartered in Loughborough, the United Kingdom.